Warning ! The cookie feature is disabled in your browser. Some features may not work properly.
Click here to learn how to activate your cookies. |
|
XXIII Congress of the ISTH & 57th Annual SSC Meeting
|
|
|
|
Webcasted Presentation
|
|
|
|
Antiplatelet Therapy: Improving the Care of ACS Patients through Evidence-Based Approaches
ISTH Accredited Course
United States of America 
Disclosure : Prof. Marco Cattaneo:
I have received support for research contracts and consulting / advisory boards from:
AstraZeneca
Daiichi Sankyo
Eli Lilly
Robert Storey:
Accumetrics - Educational grant, Consultant
AstraZeneca - Research grant, honoraria, consultant, travel
Eli Lilly/Daiichi Sankyo - Research/ educational grants, honoraria, travel, consultant
Dynabyte - Research consumables
Eisai - Consultant
The Medicines Company - Consultant
Medscape - Honoraria
Merck/Schering-Plough - Research grant, consultant
Novartis - Consultant
Sanofi-Aventis/BMS - Consultant
Paul Gurbel:
Disclosure : Research Grants / Support
Accumetrics
AstraZeneca
Daiichi Sankyo
Helena
Multiplate
Nanosphere
Portola
Pozen
sanofi-aventis
Honoraria / Consulting
Accumetrics
AstraZeneca
Bayer
Boehringer
Eli Lilly
Medtronic
Merck
Nanosphere
Novartis
Pozen
sanofi-aventis
Prof. Philippe Gabriel Steg:
Research grant: Servier
Speaking or consulting: Ablynx, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo/Lilly, Eisai, GSK, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Servier, The Medicines Company
Stockholding: Aterovax
[More]
[Less]
4 slide(s) – 00:02:13 – English – 2011-07-23
38 slide(s) – 00:13:59 – English – 2011-07-23
27 slide(s) – 00:14:32 – English – 2011-07-23
28 slide(s) – 00:15:13 – English – 2011-07-23
30 slide(s) – 00:15:58 – English – 2011-07-23
24 slide(s) – 00:20:18 – English – 2011-07-23
- Increase awareness of key results from the major outcomes trials, placing the results in context of improving care across a wide range of ACS patients
- Cite differences between current and emerging oral antiplatelet therapies in terms of platelet function mechanisms
- Gain an understanding of role and utility of biomarkers in ACS as surrogates for future clinical outcome
- Understand the role of genetics on platelet function and its implications for optimizing antiplatelet therapy and patient outcomes
| Antiplatelet Therapy: Improving the Care of ACS Patients through Evidence-Based Approaches |
Organized by the Sahlgrenska Academy, University of Gothenburg, Sweden
Course Director: Professor Karl Swedberg |
 |
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for "1" hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). |
| Distance Learning CME Program | Duration
Speaker / Country |
| Introduction & welcome | 1.32 min
Philippe Gabriel Steg / France |
| Improving Care with Oral Antiplatelet Therapy:Lessons from Recent Large Outcomes Trials. | 15.58 min
Philippe Gabriel Steg / France |
| New Mechanisms, New Agents in Antiplatelet Therapy | 13.59 min
Marco Catteneo / Italy |
| Biomarkers in ACS: Prognostic Indicators or Meaningful Endpoints | 14.32 min
Rob Storey / United Kingdom |
| Genetic Influences on Platelet Function: Recent Insights | 15.13 min
Paul Gurbel / USA |
| Panel and general discussion | 20.18 min
Chairman and faculty |
| In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities |
Supported by an unrestricted educational grant from AstraZeneca |
Determination of educational needs:
Determined by the Chairman and the faculty of the scientific session.
Oral antiplatelet therapy is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes.(ACS). However, traditional therapy with clopidogrel has several limitations, including variable inter-individual platelet effects and low inhibition of platelet aggregation. Optimal care of ACS patients requires that clinicians recognize the challenges involved in balancing the benefits and risks associated with current treatments, as well as understand the potential improvements in patient care that emerging therapeutic approaches may provide.
Target audience:
Trained cardiologists
|
SYSTEM REQUIREMENTS
- Internet enabled device
- A recent web browser (cookies and javascript enabled)
- Operating system: MacOS/Windows
- Flash Player 9+ is required in order to view the modules and complete the accredited course. If you cannot start a module please click here to download and install the current version of the Flash Player.
- Adobe Reader is required in order to open PDF files. If you cannot open a PDF File click here to download and install the latest version of Adobe Reader.
- The course cannot be completed on iOS (iPhone/iPad) If you are having trouble accessing this course, please email support@multiwebcast.com
|
|
|
|
